Cancer J. 2019 Jan/Feb;25(1):45-53. doi: 10.1097/PPO.0000000000000355.
The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However, majority of MM patients relapse, and new therapies are needed. Various agents with diverse mechanisms of action and distinct targets, including cellular therapies, monoclonal antibodies, and small molecules, are currently under investigation. In this review, we report novel drugs recently approved or under advanced investigation that will likely be incorporated in the future as new standard for MM treatment, focusing on their mechanisms of action, cellular targets, and stage of development.
多发性骨髓瘤（MM）的治疗领域在过去 15 年中发生了巨大变化，免疫调节剂和蛋白酶体抑制剂的出现改变了这一局面。然而，大多数 MM 患者会复发，因此需要新的治疗方法。目前正在研究各种具有不同作用机制和不同靶点的药物，包括细胞疗法、单克隆抗体和小分子药物。在这篇综述中，我们报告了最近批准或正在深入研究的新型药物，这些药物很可能会成为 MM 治疗的新标准，重点介绍它们的作用机制、细胞靶点和研发阶段。
